Standard BioTools (LAB) vs 10x Genomics (TXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
10x Genomics (TXG) has outperformed Standard BioTools (LAB) over the past year, gaining 182.4% versus a loss of 54.3%. Over five years, TXG leads with a -65.2% price change compared with -86.5% for LAB. 10x Genomics is the larger company by market cap ($6.81 billion vs $249.1 million), about 27.4 times the size.
10x Genomics converts more of its revenue into profit, with a net margin of -6.8% versus -87.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LAB | TXG |
|---|---|---|
| Share price | $0.631 | $51.80 |
| Market cap | $249.11M | $6.81B |
| 1-day change | +2.82% | -9.72% |
| YTD return | -50.70% | +217.60% |
| 1-year return | -54.28% | +182.44% |
| 5-year return | -86.55% | -65.20% |
| Forward P/E | — | 597.67 |
| EPS (TTM) | $-0.09 | $-0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $85.33M | $642.82M |
| Revenue growth (YoY) | -6.24% | +5.25% |
| Net income (latest FY) | $-74.90M | $-43.54M |
| Gross margin | 49.86% | 69.05% |
| Operating margin | -129.20% | -9.49% |
| Net margin | -87.77% | -6.77% |
| 52-week high | $1.72 | $102.81 |
| 52-week low | $0.39 | $15.18 |
| Distance from 52-week high | -63.31% | -49.62% |
| Analyst consensus | none | buy |
| Avg. price target upside | +113.95% | +31.54% |
| Average volume | 1.16M | 3.36M |
| Shares outstanding | 394.79M | 121.46M |
| Employees | 385 | 1,178 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- 10x Genomics is about 27.4 times larger than Standard BioTools by market value ($6.81B vs $249.11M).
- TXG has outperformed LAB by 236.7 percentage points over the past year.
- 10x Genomics is more profitable, keeping -6.8 cents of every revenue dollar as net income versus -87.8 cents for Standard BioTools.
- 10x Genomics grew revenue faster in its latest fiscal year (+5.25% vs -6.24%).
About Standard BioTools
LAB stock →Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments.
Industrials · Biotechnology: Laboratory Analytical Instruments · 385 employees
About 10x Genomics
TXG stock →10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
Industrials · Biotechnology: Laboratory Analytical Instruments · 1,178 employees
LAB vs TXG FAQ
Which is bigger, Standard BioTools or 10x Genomics?
10x Genomics (TXG) is larger, with a market capitalization of $6.81B compared with $249.11M for Standard BioTools (LAB).
Which stock has performed better over the past year, LAB or TXG?
TXG returned +182.44% over the past 12 months, compared with -54.28% for LAB (price return, excluding dividends). Past performance does not predict future results.
Are Standard BioTools and 10x Genomics in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.